Titan Spine's Endoskeleton sales up 51% in 2015; Next-generation technology on the horizon: 5 key notes

Spinal Tech

Titan Spine reported 51 percent sales increase in the Endoskeleton interbody fusion technology.

Here are five key notes:

 

1. The increase in sales shows an acceleration in the titanium interbody fusion device adoption. The technology includes Titan's unique surface technology.

 

2. Titan demonstrated the surface-etched titanium implants can reduce subsidence compared to PEEK. The Titan surface-technology also promoted an anti-inflammatory cellular environment and didn't show signs of impaction debris whereas the titanium-coated PEEK implants did have the potential to generate debris.

 

"These data are generating heightened interest and awareness of the downfalls of PEEK and have been a focus of the spine community at medical meetings and within publications over this past year, notably including our oral podium presentation at ISASS 2015 and publications in Spine and The Spine Journal," said Titan CEO Peter Ullrich.

 

3. The Endoskeleton consists of a combination of roughened topographies at the macro, micro and nano levels. The surface topographies are designed to optimize bone response and actively participate in the fusion process through upregulation of osteogenic and angiogenic factors.

 

4. There was approximately 10,000 Endoskeleton implants sold in 2015; around 44,000 Endoskeleton implants have been sold since the company's inception.

 

5. Titan Spine plans to further differentiate product offerings and release the next-generation nanoLOCK surface technology in 2016. The next generation technology is the only FDA-cleared nanotechnology for the spine. The company secured FDA clearance for the TCS for cervical fusion with integrated fixation.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers